How Preeclampsia Endangers Mother and Baby During Pregnancy

A Placental Disease Disguised as a Blood Pressure Problem

Preeclampsia complicates 2 to 8 percent of pregnancies worldwide and causes an estimated 76,000 maternal deaths and 500,000 fetal and neonatal deaths annually, according to the Preeclampsia Foundation. In the United States, the incidence has risen roughly 25 percent over the past two decades, driven partly by increasing maternal age and obesity rates. The condition is defined by new-onset hypertension (blood pressure of 140/90 mmHg or higher) after 20 weeks of gestation combined with proteinuria or other signs of end-organ damage.

Despite being classified as a hypertensive disorder, preeclampsia originates in the placenta. The elevated blood pressure and organ damage are downstream consequences of a placenta that develops abnormally in early pregnancy. Delivery of the placenta is the only cure.

The Placental Origins: Faulty Remodeling

In normal pregnancy, trophoblast cells from the developing placenta invade the spiral arteries of the uterine wall, transforming them from narrow, muscular vessels into wide, low-resistance channels. This remodeling ensures adequate blood flow to the growing fetus. In preeclampsia, this invasion is shallow and incomplete. The spiral arteries remain narrow and retain their muscular walls.

The result is a placenta under chronic oxidative stress from intermittent blood flow. The ischemic placenta releases anti-angiogenic factors, primarily soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin, into the maternal circulation. These factors antagonize pro-angiogenic proteins (VEGF and PlGF) that are essential for maintaining healthy endothelial function throughout the body.

The imbalance between anti-angiogenic and pro-angiogenic factors damages the endothelium of blood vessels system-wide, causing:

• Vasoconstriction and hypertension
• Increased vascular permeability leading to edema and proteinuria
• Platelet activation and microthrombi formation
• Glomerular endotheliosis in the kidneys
• Hepatic damage and potential capsular hemorrhage
• Blood-brain barrier disruption leading to seizure risk

Risk Factors and Who Is Most Vulnerable

The immunological component deserves attention. Preeclampsia is more common in first pregnancies, with new partners, and after prolonged intervals between pregnancies, suggesting that immune tolerance to paternal antigens in the placenta plays a role. Exposure to seminal fluid before conception may promote immune adaptation.

Warning Signs and Diagnostic Criteria

Preeclampsia can develop gradually or strike suddenly. Classic presentation includes headache, visual disturbances (blurred vision, scotomata), right upper quadrant or epigastric pain (liver involvement), and sudden swelling of the face or hands. However, many cases are detected through routine blood pressure screening at prenatal visits before symptoms appear.

Diagnostic criteria from ACOG classify preeclampsia as with or without severe features:

• Blood pressure 140/90 mmHg or higher on two occasions at least 4 hours apart
• Proteinuria: 300 mg or more in 24-hour urine or protein/creatinine ratio of 0.3 or above
• Or, in the absence of proteinuria: thrombocytopenia (platelets below 100,000), renal insufficiency (creatinine above 1.1 mg/dL), elevated liver transaminases (twice normal), pulmonary edema, or new-onset headache unresponsive to medication

Severe features include systolic blood pressure of 160 mmHg or higher, diastolic of 110 or higher, platelet count below 100,000, liver transaminases elevated to twice normal or higher, progressive renal insufficiency, pulmonary edema, or persistent cerebral or visual symptoms.

Complications: Eclampsia, HELLP, and Beyond

Eclampsia refers to new-onset tonic-clonic seizures in a woman with preeclampsia. It occurs in roughly 1 in 200 preeclampsia cases and can happen antepartum, intrapartum, or postpartum. Magnesium sulfate, administered intravenously, is the standard prophylaxis and treatment, reducing seizure risk by approximately 58 percent in the landmark Magpie trial.

HELLP syndrome is a particularly dangerous variant. The triad of hemolysis, elevated liver enzymes, and low platelets can progress rapidly to liver rupture, stroke, or multi-organ failure. Symptoms may be subtle: nausea, malaise, and right upper quadrant tenderness that can be mistaken for gastritis.

Management and the Only Cure: Delivery

Delivery of the placenta is the definitive treatment. The management decision balances maternal safety against fetal prematurity. At 37 weeks or later, delivery is recommended regardless of severity. Before 34 weeks with severe features, the goal is to administer corticosteroids for fetal lung maturity and deliver within 24 to 48 hours. Between 34 and 37 weeks, management is individualized.

Antihypertensive medications (labetalol, nifedipine, hydralazine) control acute severe hypertension to prevent stroke. Low-dose aspirin (81 to 162 mg daily), started before 16 weeks of gestation, reduces preeclampsia risk by approximately 17 percent in high-risk women and is now a standard preventive recommendation from ACOG and the USPSTF.

Preeclampsia does not end at delivery. Postpartum preeclampsia can develop or worsen in the first 6 weeks after birth. Long-term, women with a history of preeclampsia face double the risk of cardiovascular disease, stroke, and chronic hypertension later in life. Annual cardiovascular risk assessment is recommended for these women throughout their lifetime. This article is for informational purposes only. Consult a qualified professional.